• Follow the Money: Programmable mRNA Therapeutics, Neurodegenerative Disease Treatment, More

    Aug 27 | Diagnostics World | Strand Therapeutics will advance their pipeline of STX-001, a programmable mRNA therapy that expresses the cytokine interleukin-12 (IL-12) directly from the tumor microenvironment; Jocasta Therapeutics plan to further develop a - Klotho, a protein therapeutic targeting cognitive decline in neurodegenerative diseases; and more. More

  • Roche Receives FDA Clearance, Dana-Farber Develops Multiple Myeloma Blood Test, More

    Aug 26 | Diagnostics World | Roche announced the US Food and Drug Administration (FDA) 510(k) clearance for the cobas Respiratory 4-flex; Dana-Farber Cancer Institute researchers have developed a blood test that could transform the diagnosis and monitoring of multiple myeloma; and more. More

  • Boston Children’s Hospital, Broad Clinical Labs, Dana-Farber Cancer Institute Launch Research Initiative

    Aug 21 | Diagnostics World | Earlier this month, Boston Children’s Hospital, Broad Clinical Labs, and Dana-Farber Cancer Institute announced the formation of a collaborative clinical research and testing initiative, Boston Research in Innovative Genomics for Hematologic and Tumor Sequencing (BrightSeq). More

  • MILO Helping Artificial Intelligence Reach Its Diagnostic Potential

    Aug 20 | Diagnostics World | Efforts to couple patient-level data with machine learning (ML) are going to accelerate “100-plus-fold” over the next decade, dramatically improving evidence-based decision-making and demonstrably improving patient care. In the diagnostics field, supervised learning that leverages classification represents the bulk of this work currently and may even suggest the algorithms best suited to the task at hand. More

  • Ultima Genomics ppmSeq Stats Preprint

    Aug 19 | Diagnostics World | Ultima Genomics published updates on the single-nucleotide variant (SNV) detection capabilities of its ppmSeq technology and demonstrated ctDNA detection limits for ppmSeq, which extend beyond the limits of currently available minimal residual disease assays. More

  • More Personalized Medicine Possible Using Large Language Models

    Aug 14 | Diagnostics World | With the advent of large language models (LLMs), expert human abstractors are meeting their match when it comes to accurately identifying cancer progression events from electronic health records (EHRs). That’s one of the big surprises emerging from a study presented by Aaron Cohen, M.D., a practicing oncologist and head of oncology research at Flatiron Health, at a recent artificial intelligence and machine learning conference of the American Association for Cancer Research. More

  • Multi-Purpose Platform Looks to Speed Medical Devices to Market

    Aug 12 | Diagnostics World | Like a smartphone housing many software applications, a multi-purpose platform looks to be the launchpad for a potentially huge number of medical devices. The Openwater system, under development for nearly a decade, holds promise in noninvasively diagnosing and treating disease using infrared light and low-intensity focused ultrasound (LIFU). More

  • Johns Hopkins Develops Multimodal AI Model That Predicts Sudden Cardiac Arrest

    Aug 07 | Diagnostics World | Researchers at Johns Hopkins University have developed Multimodal Artificial intelligence for ventricular Arrhythmia Risk Stratification (MAARS), a deep learning approach to predict lethal arrhythmia in patients with HCM by analyzing multimodal medical data. More

  • Alzheimer’s Conference Highlights New Diagnostics, Treatments

    Aug 06 | Diagnostics World | The Alzheimer's Association International Conference was held last week in Toronto and researchers and companies gathered to present their progress in the fight to diagnose and treat Alzheimer’s disease. Among the timely new developments: new products from Quanterix; pre-clinical data from AltPep, OncoC4, and NKGen Biotech; pipeline updates from Eisai, Biogen, and Roche; and more. More

  • AI Algorithm Advances Cancer Diagnostics Through Rapid Cell Type Identification

    Aug 05 | Diagnostics World | Researchers at Virginia Commonwealth University have developed an artificial intelligence tool that could revolutionize cancer diagnostics by rapidly identifying distinct cell types in tissue biopsies, potentially transforming how clinicians make treatment decisions and predict patient responses to therapy. More
View more articles

 
DXX-Industry-spotlight

merck


Custom Diagnostic Antibody Development & Manufacturing Services

Overcome Process Challenges by outsourcing your custom antibody production to us. How partnering with an antibody production expert can improve your assay, accelerate launch, and maintain your manufacturing.

Learn more